Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 447 entries
Sorted by: Best Match Show Resources per page
Outcomes of citalopram dosage risk mitigation in a veteran population

veteran

Adabag S.
GSID: 8GLvSU9G9WEJ
TS Rector, S Adabag, F Cunningham… - American Journal of …, 2016 - Am Psychiatric Assoc

Objective: A public safety communication issued by the Food and Drug Administration declared that citalopram dosages exceeding 40 mg/day were no longer considered safe because …

Cite
Rector, T. S., Adabag, S., Cunningham, F., Nelson, D., & Dieperink, E. (2016). Outcomes of citalopram dosage risk mitigation in a veteran population. American Journal of Psychiatry, 173(9), 896-902.
Rector, Thomas S., et al. "Outcomes of citalopram dosage risk mitigation in a veteran population." American Journal of Psychiatry 173.9 (2016): 896-902.
Copy Download .nbib Format: MLA
Effects of citalopram on heart rate variability in women with generalized anxiety disorder.

ARYA atherosclerosis

Ranjbar F, Akbarzadeh F, Zakeri F, Farahbakhsh M, Ali Nazari M.
PMID: 26405453
ARYA Atheroscler. 2015 May;11(3):196-203.

BACKGROUND: Heart rate variability (HRV) is defined as variations in R-R interval with time. Dysautonomia is common in patients with psychiatric disorders such as depression and anxiety. Using HRV analysis, recent studies showed that in anxiety disorders, the vagal...

Cite
Ranjbar F, Akbarzadeh F, Zakeri F, et al. Effects of citalopram on heart rate variability in women with generalized anxiety disorder. ARYA Atheroscler. 2015;11(3):196-203
Ranjbar, F., Akbarzadeh, F., Zakeri, F., Farahbakhsh, M., & Ali Nazari, M. (2015). Effects of citalopram on heart rate variability in women with generalized anxiety disorder. ARYA atherosclerosis, 11(3), 196-203.
Ranjbar, Fatemeh, et al. "Effects of citalopram on heart rate variability in women with generalized anxiety disorder." ARYA atherosclerosis vol. 11,3 (2015): 196-203.
Ranjbar F, Akbarzadeh F, Zakeri F, Farahbakhsh M, Ali Nazari M. Effects of citalopram on heart rate variability in women with generalized anxiety disorder. ARYA Atheroscler. 2015 May;11(3):196-203. PMID: 26405453; PMCID: PMC4568193.
Copy Download .nbib Format: NLM
Association of citalopram with congenital anomalies: A meta-analysis.

Obstetrics & gynecology science

Kang HH, Ahn KH, Hong SC, Kwon BY, Lee EH, Lee JS, Oh MJ, Kim HJ.
PMID: 28344955
Obstet Gynecol Sci. 2017 Mar;60(2):145-153. doi: 10.5468/ogs.2017.60.2.145. Epub 2017 Mar 16.

OBJECTIVE: The antenatal use of citalopram, a widely prescribed selective serotonin reuptake inhibitor, has been suspected to be associated with congenital, particularly cardiac, anomalies. This study aimed to prove the association between citalopram use and congenital anomalies.METHODS: We searched...

Cite
Kang HH, Ahn KH, Hong SC, et al. Association of citalopram with congenital anomalies: A meta-analysis. Obstet Gynecol Sci. 2017;60(2):145-153doi: 10.5468/ogs.2017.60.2.145.
Kang, H. H., Ahn, K. H., Hong, S. C., Kwon, B. Y., Lee, E. H., Lee, J. S., Oh, M. J., & Kim, H. J. (2017). Association of citalopram with congenital anomalies: A meta-analysis. Obstetrics & gynecology science, 60(2), 145-153. https://doi.org/10.5468/ogs.2017.60.2.145
Kang, Hyun-Hye, et al. "Association of citalopram with congenital anomalies: A meta-analysis." Obstetrics & gynecology science vol. 60,2 (2017): 145-153. doi: https://doi.org/10.5468/ogs.2017.60.2.145
Kang HH, Ahn KH, Hong SC, Kwon BY, Lee EH, Lee JS, Oh MJ, Kim HJ. Association of citalopram with congenital anomalies: A meta-analysis. Obstet Gynecol Sci. 2017 Mar;60(2):145-153. doi: 10.5468/ogs.2017.60.2.145. Epub 2017 Mar 16. PMID: 28344955; PMCID: PMC5364096.
Copy Download .nbib Format: NLM
Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.

Journal of personalized medicine

Aka I, Bernal CJ, Carroll R, Maxwell-Horn A, Oshikoya KA, Van Driest SL.
PMID: 29099060
J Pers Med. 2017 Nov 02;7(4). doi: 10.3390/jpm7040014.

Cytochrome P450 (CYP) enzymes are commonly involved in drug metabolism, and genetic variation in the genes encoding CYPs are associated with variable drug response. While genotype-guided therapy has been clinically implemented in adults, these associations are less well established...

Cite
Aka I, Bernal CJ, Carroll R, et al. Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. J Pers Med. 2017;7(4)doi: 10.3390/jpm7040014.
Aka, I., Bernal, C. J., Carroll, R., Maxwell-Horn, A., Oshikoya, K. A., & Van Driest, S. L. (2017). Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. Journal of personalized medicine, 7(4), . https://doi.org/10.3390/jpm7040014
Aka, Ida, et al. "Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children." Journal of personalized medicine vol. 7,4 (2017). doi: https://doi.org/10.3390/jpm7040014
Aka I, Bernal CJ, Carroll R, Maxwell-Horn A, Oshikoya KA, Van Driest SL. Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. J Pers Med. 2017 Nov 02;7(4). doi: 10.3390/jpm7040014. PMID: 29099060; PMCID: PMC5748626.
Copy Download .nbib Format: NLM
Comparison of escitalopram and citalopram efficacy: A meta-analysis.

International journal of psychiatry in clinical practice

Auquier P, Robitail S, Llorca PM, Rive B.
PMID: 24930412
Int J Psychiatry Clin Pract. 2003;7(4):259-68. doi: 10.1080/13651500310003408.

OBJECTIVE Escitalopram is a new selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) and panic disorder. Escitalopram is the therapeutically active enantiomer of citalopram. Its efficacy in the treatment of MDD was compared...

Cite
Auquier P, Robitail S, Llorca PM, et al. Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatry Clin Pract. 2003;7(4):259-68doi: 10.1080/13651500310003408.
Auquier, P., Robitail, S., Llorca, P. M., & Rive, B. (2003). Comparison of escitalopram and citalopram efficacy: A meta-analysis. International journal of psychiatry in clinical practice, 7(4), 259-68. https://doi.org/10.1080/13651500310003408
Auquier, Pascal, et al. "Comparison of escitalopram and citalopram efficacy: A meta-analysis." International journal of psychiatry in clinical practice vol. 7,4 (2003): 259-68. doi: https://doi.org/10.1080/13651500310003408
Auquier P, Robitail S, Llorca PM, Rive B. Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatry Clin Pract. 2003;7(4):259-68. doi: 10.1080/13651500310003408. PMID: 24930412.
Copy Download .nbib Format: NLM
Selegiline-citalopram combination in patients with Parkinson's disease and major depression.

International journal of psychiatry in clinical practice

Rihmer Maria Satori Peter Pestality Z.
PMID: 24921447
Int J Psychiatry Clin Pract. 2000;4(2):123-5. doi: 10.1080/13651500050518280.

INTRODUCTION: We evaluated the efficacy and safety of the selegiline citalopram combination in the treatment of major depression in patients with Parkinson's disease.METHOD: Eight consecutive depressed outpatients who had received previously selegiline monotherapy or (one patient) selegiline-levodopa combination (the...

Cite
Rihmer Maria Satori Peter Pestality Z. Selegiline-citalopram combination in patients with Parkinson's disease and major depression. Int J Psychiatry Clin Pract. 2000;4(2):123-5doi: 10.1080/13651500050518280.
Rihmer Maria Satori Peter Pestality, Z. (2000). Selegiline-citalopram combination in patients with Parkinson's disease and major depression. International journal of psychiatry in clinical practice, 4(2), 123-5. https://doi.org/10.1080/13651500050518280
Rihmer Maria Satori Peter Pestality, Z. "Selegiline-citalopram combination in patients with Parkinson's disease and major depression." International journal of psychiatry in clinical practice vol. 4,2 (2000): 123-5. doi: https://doi.org/10.1080/13651500050518280
Rihmer Maria Satori Peter Pestality Z. Selegiline-citalopram combination in patients with Parkinson's disease and major depression. Int J Psychiatry Clin Pract. 2000;4(2):123-5. doi: 10.1080/13651500050518280. PMID: 24921447.
Copy Download .nbib Format: NLM
Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram.

International journal of psychiatry in clinical practice

Lançon C, Verpillat P, Annemans L, Despiegel N, François C.
PMID: 24941275
Int J Psychiatry Clin Pract. 2007;11(1):44-52. doi: 10.1080/13651500600874527.

Objective. Escitalopram is the most selective of the serotonin reuptake inhibitors. Methods. We review all the clinical trials (three pivotal placebo-controlled trials with citalopram as an active reference, one long-term non-inferiority study and one head-to-head superiority study) that include...

Cite
Lançon C, Verpillat P, Annemans L, et al. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. Int J Psychiatry Clin Pract. 2007;11(1):44-52doi: 10.1080/13651500600874527.
Lançon, C., Verpillat, P., Annemans, L., Despiegel, N., & François, C. (2007). Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. International journal of psychiatry in clinical practice, 11(1), 44-52. https://doi.org/10.1080/13651500600874527
Lançon, Christophe, et al. "Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram." International journal of psychiatry in clinical practice vol. 11,1 (2007): 44-52. doi: https://doi.org/10.1080/13651500600874527
Lançon C, Verpillat P, Annemans L, Despiegel N, François C. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. Int J Psychiatry Clin Pract. 2007;11(1):44-52. doi: 10.1080/13651500600874527. PMID: 24941275.
Copy Download .nbib Format: NLM
Quantitative ROESY analysis of computational models: structural studies of citalopram and β-cyclodextrin complexes by (1) H-NMR and computational methods.

Magnetic resonance in chemistry : MRC

Ali SM, Shamim S.
PMID: 26105793
Magn Reson Chem. 2015 Jul;53(7):526-35. doi: 10.1002/mrc.4250.

Complexation of racemic citalopram with β-cyclodextrin (β-CD) in aqueous medium was investigated to determine atom-accurate structure of the inclusion complexes. (1) H-NMR chemical shift change data of β-CD cavity protons in the presence of citalopram confirmed the formation of...

Cite
Ali SM, Shamim S. Quantitative ROESY analysis of computational models: structural studies of citalopram and β-cyclodextrin complexes by (1) H-NMR and computational methods. Magn Reson Chem. 2015;53(7):526-35doi: 10.1002/mrc.4250.
Ali, S. M., & Shamim, S. (2015). Quantitative ROESY analysis of computational models: structural studies of citalopram and β-cyclodextrin complexes by (1) H-NMR and computational methods. Magnetic resonance in chemistry : MRC, 53(7), 526-35. https://doi.org/10.1002/mrc.4250
Ali, Syed Mashhood, and Shamim, Shazia. "Quantitative ROESY analysis of computational models: structural studies of citalopram and β-cyclodextrin complexes by (1) H-NMR and computational methods." Magnetic resonance in chemistry : MRC vol. 53,7 (2015): 526-35. doi: https://doi.org/10.1002/mrc.4250
Ali SM, Shamim S. Quantitative ROESY analysis of computational models: structural studies of citalopram and β-cyclodextrin complexes by (1) H-NMR and computational methods. Magn Reson Chem. 2015 Jul;53(7):526-35. doi: 10.1002/mrc.4250. PMID: 26105793.
Copy Download .nbib Format: NLM
A Pilot Study of Citalopram Treatment in Preventing Relapse of Depressive Episode after Acute Treatment.

Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent

Cheung A, Levitt A, Cheng M, Santor D, Kutcher S, Dubo E, Jane Garland E, Weiss M, Kiss A.
PMID: 27047552
J Can Acad Child Adolesc Psychiatry. 2016;25(1):11-6. Epub 2016 Feb 01.

PURPOSE: To examine the benefit of continuation treatment with citalopram in adolescents 13 to 18 years of age with major depression using a multi-site randomized placebo controlled discontinuation design.METHODS: Subjects with depression who responded to open label treatment with...

Cite
Cheung A, Levitt A, Cheng M, et al. A Pilot Study of Citalopram Treatment in Preventing Relapse of Depressive Episode after Acute Treatment. J Can Acad Child Adolesc Psychiatry. 2016;25(1):11-6
Cheung, A., Levitt, A., Cheng, M., Santor, D., Kutcher, S., Dubo, E., Jane Garland, E., Weiss, M., & Kiss, A. (2016). A Pilot Study of Citalopram Treatment in Preventing Relapse of Depressive Episode after Acute Treatment. Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent, 25(1), 11-6.
Cheung, Amy, et al. "A Pilot Study of Citalopram Treatment in Preventing Relapse of Depressive Episode after Acute Treatment." Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent vol. 25,1 (2016): 11-6.
Cheung A, Levitt A, Cheng M, Santor D, Kutcher S, Dubo E, Jane Garland E, Weiss M, Kiss A. A Pilot Study of Citalopram Treatment in Preventing Relapse of Depressive Episode after Acute Treatment. J Can Acad Child Adolesc Psychiatry. 2016;25(1):11-6. Epub 2016 Feb 01. PMID: 27047552; PMCID: PMC4791101.
Copy Download .nbib Format: NLM
Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.

American journal of neurodegenerative disease

Lauterbach EC.
PMID: 27073741
Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016.

Anxiety is common in the Mild Cognitive Impairment (MCI) stage of Alzheimer's disease (AD) and the pre-motor stages of Parkinson's disease (PD). A concomitant and possible cause of this anxiety is microglial activation, also considered a key promoter of...

Cite
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016;5(1):29-51
Lauterbach, E. C. (2016). Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. American journal of neurodegenerative disease, 5(1), 29-51.
Lauterbach, Edward C. "Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease." American journal of neurodegenerative disease vol. 5,1 (2016): 29-51.
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016. PMID: 27073741; PMCID: PMC4788730.
Copy Download .nbib Format: NLM
Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder.

Iranian journal of psychiatry and behavioral sciences

Khoonsari H, Oghazian MB, Kargar M, Moin M, Khalili H, Alimadadi A, Torkamandi H, Ghaeli P.
PMID: 26288644
Iran J Psychiatry Behav Sci. 2015 Jun;9(2):e230. doi: 10.17795/ijpbs230. Epub 2015 Jun 23.

BACKGROUND: Patients with mixed anxiety-depressive disorder (MADD) suffer both anxiety and depression. Antidepressants, especially, selective serotonin reuptake inhibitors are among agents of choice for treating this condition.OBJECTIVES: This study compared the efficacy of Cipram® with its generic, citalopram.PATIENTS AND...

Cite
Khoonsari H, Oghazian MB, Kargar M, et al. Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder. Iran J Psychiatry Behav Sci. 2015;9(2):e230doi: 10.17795/ijpbs230.
Khoonsari, H., Oghazian, M. B., Kargar, M., Moin, M., Khalili, H., Alimadadi, A., Torkamandi, H., & Ghaeli, P. (2015). Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder. Iranian journal of psychiatry and behavioral sciences, 9(2), e230. https://doi.org/10.17795/ijpbs230
Khoonsari, Hasan, et al. "Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder." Iranian journal of psychiatry and behavioral sciences vol. 9,2 (2015): e230. doi: https://doi.org/10.17795/ijpbs230
Khoonsari H, Oghazian MB, Kargar M, Moin M, Khalili H, Alimadadi A, Torkamandi H, Ghaeli P. Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder. Iran J Psychiatry Behav Sci. 2015 Jun;9(2):e230. doi: 10.17795/ijpbs230. Epub 2015 Jun 23. PMID: 26288644; PMCID: PMC4539397.
Copy Download .nbib Format: NLM
Serotonergic antidepressants and increased bleeding risk in patients undergoing breast biopsy.

Therapeutic advances in psychopharmacology

Mahdanian AA, Looper KJ, Bacon SL, Mesurolle B, Meterissian SH, Rej S.
PMID: 26834966
Ther Adv Psychopharmacol. 2015 Dec;5(6):332-8. doi: 10.1177/2045125315612014.

OBJECTIVES: Recent investigations have shown that serotonergic antidepressant (SAd) use may increase the risk of peri-operative bleeding events. Our objective was to evaluate the possibility of a similar association in patients undergoing radiologic breast biopsies.METHODS: We used data from...

Cite
Mahdanian AA, Looper KJ, Bacon SL, et al. Serotonergic antidepressants and increased bleeding risk in patients undergoing breast biopsy. Ther Adv Psychopharmacol. 2015;5(6):332-8doi: 10.1177/2045125315612014.
Mahdanian, A. A., Looper, K. J., Bacon, S. L., Mesurolle, B., Meterissian, S. H., & Rej, S. (2015). Serotonergic antidepressants and increased bleeding risk in patients undergoing breast biopsy. Therapeutic advances in psychopharmacology, 5(6), 332-8. https://doi.org/10.1177/2045125315612014
Mahdanian, Artin A, et al. "Serotonergic antidepressants and increased bleeding risk in patients undergoing breast biopsy." Therapeutic advances in psychopharmacology vol. 5,6 (2015): 332-8. doi: https://doi.org/10.1177/2045125315612014
Mahdanian AA, Looper KJ, Bacon SL, Mesurolle B, Meterissian SH, Rej S. Serotonergic antidepressants and increased bleeding risk in patients undergoing breast biopsy. Ther Adv Psychopharmacol. 2015 Dec;5(6):332-8. doi: 10.1177/2045125315612014. PMID: 26834966; PMCID: PMC4722505.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 447 entries